For CYP26B1 negative tumours (n = 200) the mean survival was 143 months (95%CI = 127–158 months), for CYP26B1 weak tumours (n = 186) the mean survival was 106 months (95%CI = 94–116 months), for CYP26B1 moderate tumours (n = 87) the mean survival was 96 months (95%CI = 82–112 months) and for strongly expressing CYP26B1 tumours (n = 49) the mean survival was 77 months (95%CI 56–98 months). This evidence concerns the gene CYP26B1 and neoplasm.